Evidence map›Paper›PMID 38505854›Full record

ArticleACS medicinal chemistry letters2024

Innovations in Pharmacology: Enhancing Bioavailability and Efficacy through Novel Compositions.

Robert B Kargbo

Abstract readEditorial
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Enhancing the bioavailability ofAnnals of medicine and surgery (2012) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Robert B KargboUsona Institute, Fitchburg, Wisconsin 53711-5300, United States.ORCID https://orcid.org/0000-0002-5539-6343

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This Patent Highlight explores ground-breaking advancements in pharmaceutical compositions, revealing the integration of serotonergic tryptamine compounds and microbial-produced biosurfactants. These innovations aim to enhance the bioavailability and efficacy of health-promoting substances significantly. The article examines the existing challenges in pharmacological treatments and the inventive solutions proposed by recent developments. It discusses compositions that reduce inflammation and improve mental and physical health, the use of serotonergic tryptamine compounds in mood and neurological disorders, and novel methods for boosting bioavailability with biosurfactants. The article provides an overview of these strategies and their potential to influence future pharmacological approaches.

Identifiers

PMID38505854
PMCPMC10945534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.